Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allergan
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
50 years of age or older with subfoveal choroidal neovascularization (CNV) (classic and/or occult) secondary to AMD
Visual Acuity between 20/40 and 20/400 in the study eye
You may not be if
Any intraocular surgery within 3 months
Glaucoma
Cataract
High eye pressure
Uncontrolled systemic disease
Clareo Health | Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
